Kenvue Inc. $KVUE Shares Sold by Ingalls & Snyder LLC

Ingalls & Snyder LLC decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 0.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 622,666 shares of the company’s stock after selling 4,685 shares during the quarter. Ingalls & Snyder LLC’s holdings in Kenvue were worth $13,032,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Kenvue by 4.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after purchasing an additional 4,034 shares during the period. Renaissance Capital LLC lifted its holdings in Kenvue by 8.3% in the second quarter. Renaissance Capital LLC now owns 629,177 shares of the company’s stock valued at $13,169,000 after acquiring an additional 48,267 shares during the period. Farther Finance Advisors LLC lifted its holdings in Kenvue by 80.7% in the second quarter. Farther Finance Advisors LLC now owns 36,196 shares of the company’s stock valued at $758,000 after acquiring an additional 16,164 shares during the period. Arlington Partners LLC acquired a new position in Kenvue in the second quarter valued at approximately $2,110,000. Finally, Cornell Pochily Investment Advisors Inc. lifted its holdings in Kenvue by 144.6% in the second quarter. Cornell Pochily Investment Advisors Inc. now owns 33,173 shares of the company’s stock valued at $694,000 after acquiring an additional 19,609 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

KVUE has been the subject of a number of analyst reports. Evercore ISI decreased their price target on Kenvue from $23.00 to $18.00 and set an “in-line” rating for the company in a report on Tuesday, September 23rd. Rothschild & Co Redburn raised Kenvue from a “neutral” rating to a “buy” rating and decreased their price target for the company from $22.50 to $22.00 in a report on Friday, September 26th. Deutsche Bank Aktiengesellschaft set a $18.00 price target on Kenvue in a report on Friday. Citigroup decreased their price target on Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, October 9th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a research report on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $20.75.

Kenvue Stock Down 0.6%

Shares of KVUE opened at $15.00 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. Kenvue Inc. has a one year low of $14.05 and a one year high of $25.17. The stock has a market capitalization of $28.78 billion, a price-to-earnings ratio of 20.26, a PEG ratio of 2.16 and a beta of 0.72. The stock has a 50 day moving average price of $17.91 and a 200 day moving average price of $20.79.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion during the quarter, compared to analysts’ expectations of $3.94 billion. During the same period in the previous year, the business earned $0.32 earnings per share. The firm’s revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were paid a $0.2075 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 annualized dividend and a dividend yield of 5.5%. Kenvue’s dividend payout ratio is currently 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.